Vera Therapeutics (VERA) Equity Average (2020 - 2026)

Vera Therapeutics has reported Equity Average for 7 years, with the latest figure at $552.1 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 0.71% year-over-year to $552.1 million; the trailing twelve-month figure through Mar 2026 stood at $552.1 million (down 0.71% YoY), and the FY2025 full-year result was $590.8 million, up 74.07% from the prior year.
• Equity Average for Q1 2026 stood at $552.1 million, up from $501.7 million in the prior quarter.
• The five-year high for Equity Average was $556.1 million in Q1 2025, with the low at $91.3 million in Q4 2022.
• Historically, Equity Average has averaged $282.4 million across 5 years, with a median of $227.6 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average jumped 22143.84% — and 2026, when it retreated 0.71%.
• Vera Therapeutics' Equity Average stood at $91.3 million in 2022, then gained by 23.42% to $112.7 million in 2023, then soared by 284.31% to $433.1 million in 2024, then advanced by 15.84% to $501.7 million in 2025, then rose by 10.05% to $552.1 million in 2026.
• The last three Equity Average figures came in at $552.1 million (Q1 2026), $501.7 million (Q4 2025), and $433.6 million (Q3 2025), per Business Quant data.